Introduction {#s1}
============

Natural products are an important source for the development of pharmaceutical drugs, especially in oncology; half of all anticancer drugs developed since the 1940s are natural products or derivatives of natural products ([@bib41]). Compounds with anticancer activity can be readily identified in cytotoxicity assays and other phenotypic screens ([@bib31]; [@bib21]). To use these small molecules as anticancer drug leads or to identify new chemotherapy molecular targets, it is essential to characterize the molecular mechanism of action (MOA) that underlies cytotoxicity ([@bib49]; [@bib13]). However, as unraveling the MOA of bioactive small molecules remains challenging and time consuming ([@bib49]; [@bib63]), the MOA of many natural products that display promising anticancer activities in phenotypic screens remains uncharacterized ([@bib51]). An example of such a natural product is ophiobolin A (OPA), a plant toxin isolated from pathogenic fungi of the *Bipolaris* genus which displays cytotoxicity at nanomolar concentrations against a range of cancer cell lines ([@bib8]; [@bib15]). OPA induces paraptosis, a form of non-apoptotic cell death, in glioblastoma cells and displays antitumor activity in a mouse glioblastoma model ([@bib14]; [@bib20]). The toxicity of OPA to plants is believed to involve calmodulin inhibition via formation of a covalent adduct between OPA and specific lysine side chains ([@bib36]). More recently, it has been shown in synthetic studies that primary amines react with the 1,4-dicarbonyl moiety of OPA to form covalent adducts and that this moiety is critical for animal cell cytotoxicity, leading the authors to suggest that the MOA of OPA in animal cells is through covalent modification of an unknown intracellular target protein ([@bib20]). In conclusion, OPA represents an interesting candidate for the treatment of glioblastomas that are resistant to classical pro-apoptotic therapeutic approaches, but the lack of information on cellular targets of OPA impedes any further development.

Genetic screens represent an unbiased genome-wide approach to identify molecular targets involved in small molecule MOA but have been mainly limited to application in genetically tractable organisms such as *Saccharomyces cerevisiae *([@bib47]; [@bib34]). Recent technical breakthroughs, such as insertional mutagenesis in haploid cells ([@bib17], [@bib18]) and CRISPR-Cas9 genome editing ([@bib59]; [@bib50]; [@bib25]; [@bib53]) have revolutionized the use of genetic screens in human cell lines to facilitate the study of the MOA of bioactive molecules in model systems more relevant to human disease ([@bib42]).

To unravel the MOA of OPA, we took advantage of a genome-wide strategy in human cells to identify genes that are required for OPA to exert its cytotoxic effect. We used insertional mutagenesis in the near-haploid human cell line KBM7 to generate loss-of-function mutants and then selected for growth of cell lines resistant to OPA treatment ([@bib18]). We discovered that inactivation of the pathway for de novo synthesis of phosphatidylethanolamine (PE), also named the Kennedy pathway, confers resistance to OPA. Increased OPA resistance was correlated with decreased cellular PE levels. Surprisingly, we determined that the molecular target of OPA is PE itself; OPA forms a covalent adduct with PE in human cells. This work illustrates the power of unbiased genetic screens in human cells in discovering novel MOAs of compounds identified in phenotypic screens.

Results {#s2}
=======

Identification of targets of anticancer drugs in human cells {#s2-1}
------------------------------------------------------------

Loss-of-function genetic screens in human KBM7 cells have been used to identify cellular factors that are necessary for entry of viruses and bacterial toxins, and transporters of small molecules, but rarely to identify the molecular targets of small molecule drugs ([@bib18]; [@bib42]; [@bib60]; [@bib45]; [@bib11]). Before applying the screen to studies of compounds of unknown MOA displaying anticancer activity, we first determined whether such screens can robustly identify genes involved in the cytotoxicity of anticancer drugs with well-characterized MOAs. Briefly, we used a retroviral gene-trap approach to generate approximately 75 million insertions in the near-haploid human cell line KBM7, covering more than 95% of all expressed genes ([@bib18]). This library of loss-of-function cell lines was treated with a toxic dose of anticancer drug and resistant mutants were allowed to grow over 3 weeks. Retroviral insertion sites were identified by amplification of the genomic sequence flanking the insertion site, high-throughput sequencing, and mapping to the human genome. Insertions in exonic regions or in the sense orientation of intronic regions are typically expected to cause gene inactivation ([@bib17]). For each gene locus, we calculated an enrichment p-value by comparing the number of inactivating insertions in the pooled drug-resistant cells to the number of such insertions in mutagenized cells before selection. This enrichment p-value allows the identification of genes whose inactivation renders cells resistant to the toxic effects of the small molecule tested ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

We performed screens with anticancer drugs including topoisomerase inhibitors (topotecan, etoposide, and doxorubicin), a proteasome inhibitor (bortezomib), an antimetabolite (gemcitabine) and a platinum-based DNA crosslinking agent (oxaliplatin). As expected, we observed enrichment of inactivating insertions in genes known to play a role in the MOA of these anticancer compounds ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). For instance, doxorubicin and etoposide induce cytotoxicity by forming a ternary complex with DNA and the enzyme topoisomerase IIA ([@bib43]). In both screens, we detected a significant enrichment of inactivating insertions in gene *TOP2A*, which encodes topoisomerase IIA ([Figure 1---figure supplement 2a--b](#fig1s2){ref-type="fig"}). Bortezomib kills cancer cells by proteasome inhibition ([@bib1]) and, accordingly, we observed a significant enrichment of inactivating insertions in genes encoding proteasome subunits ([Figure 1---figure supplement 2d](#fig1s2){ref-type="fig"}). In addition to targets of anticancer drugs, the screens also identified transporters and genes known to metabolize the drug tested ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Thus, loss-of-function screens in KBM7 cells are a powerful way to initiate MOA studies of anticancer compounds.

Kennedy pathway mutants are resistant to OPA {#s2-2}
--------------------------------------------

We then used the KBM7 screening platform to investigate the mechanism of cytotoxicity of OPA, isolating human cells containing insertions that rendered cells resistant to OPA treatment. Three genes had a significant enrichment of retroviral insertions: ethanolamine kinase 1 (*ETNK1,* p = 7.2 × 10^−12^), phosphate cytidylyltransferase 2, ethanolamine (*PCYT2,* p = 4.0 × 10^−7^), and ethanolaminephosphotransferase 1 (*EPT1,* p = 4.0 × 10^−7^) ([Figure 1a](#fig1){ref-type="fig"}). These three genes encode the three enzymes required for the de novo synthesis of PE, also known as the Kennedy pathway ([@bib24]) ([Figure 1b](#fig1){ref-type="fig"}). To test the robustness of this result, we repeated screens at different concentrations of OPA; at least one gene in the Kennedy pathway was enriched above background at every concentration tested ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}).10.7554/eLife.14601.003Figure 1.Identification of a genetic interaction between ophiobolin A (OPA) and the Kennedy pathway using a loss-of-function genetic screen in the near-haploid human cell line KBM7.(**a**) A collection of loss-of-function mutants generated in KBM7 cells using retroviral insertional mutagenesis was treated with 388 nM OPA. Resistant clones were allowed to expand for 3 weeks and retroviral insertion sites were identified by high-throughput sequencing. For each gene, an enrichment factor (p-value) was calculated to quantify the enrichment of inactivating insertions in the pool of resistant clones compared to the number existing before selection. Each bubble represents a gene and the diameter of the bubble is proportional to the number of unique insertion sites in the pool of resistant clones (for *ETNK1*, N = 11). Genes are ordered on the x axis by chromosomal location ([Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). (**b**) The Kennedy pathway: de novo synthesis of phosphatidylethanolamine. (**c--e**) Characterization of KBM7 clonal cell lines resistant to OPA treatment with inactivating mutations in either *PCYT2* or *ETNK1*, referred to as PCYT2^GT^ and ETNK1^GT^. (**c**) Quantification of relative *PCYT2* and *ETNK1* mRNA levels by RT-qPCR, normalized to levels in wild-type KBM7 (WT). (**d**) Cell viability measurement after 72 hr of treatment with OPA (or DMSO vehicle) using a luciferase-based assay quantifying ATP content. The viability of each vehicle-treated cell line was normalized to 1. (**e**) Determination of cellular phosphatidylethanolamine (PE) content by total lipid extraction, separation of phospholipids by thin layer chromatography and quantification of phospholipids by phosphorus content analysis. PE content is displayed as a percentage of total phospholipids. (**f**) Expression of PCYT2 in PCYT2^GT^ cells restores OPA sensitivity. Constructs expressing either PCYT2 or GFP (control) were delivered to WT or PCYT2^GT^ cells by lentiviral transduction. The viability of each cell line was assayed using a luciferase-based assay quantifying ATP content after 72 hr of treatment with OPA (or DMSO vehicle). \'---\' denotes non-transduced cell lines. (**c--f**) Results were obtained from three independent experiments (**c** and **e**) or from assays performed in triplicate (**d** and **f**) and data represent mean values ± standard deviation.**DOI:** [http://dx.doi.org/10.7554/eLife.14601.003](10.7554/eLife.14601.003)10.7554/eLife.14601.004Figure 1---source data 1.Source data for the ophiobolin A (OPA) loss-of-function KBM7 screen.**DOI:** [http://dx.doi.org/10.7554/eLife.14601.004](10.7554/eLife.14601.004)10.7554/eLife.14601.005Figure 1---figure supplement 1.Illustration of loss-of-function genetic screens in haploid human KBM7 cells ([@bib17], [@bib18]).Near-haploid KBM7 cells are infected with a gene-trap retrovirus to generate random insertions. Insertions in exonic regions or in the sense orientation in intronic regions typically cause loss-of-function mutations. Mutagenized KBM7 cells are treated with a toxic dose of a molecule of interest and resistant clones are allowed to expand into colonies. Retroviral insertion sites in the pooled resistant population are identified by amplification of flanking genomic DNA by inverse PCR, high-throughput sequencing, and mapping to the human genome. For each gene locus, an enrichment p-value is calculated using Fisher\'s exact test by comparing the number of unique inactivating insertions in the pool of resistant cells to the number of unique inactivating insertions in mutagenized cells before selection. The location of retroviral insertion sites was analyzed in 5 million mutagenized cells before selection (representing 5% of the number of cells used per screen) and 142,800 unique insertions were identified, 38,628 of which were gene inactivating mutations (Materials and methods). This collection of 38,628 unique inactivating insertions was used in the calculation of enrichment p-values ([Figure 1---figure supplement 1---source data 1](#SD2-data){ref-type="supplementary-material"}).**DOI:** [http://dx.doi.org/10.7554/eLife.14601.005](10.7554/eLife.14601.005)10.7554/eLife.14601.006Figure 1---figure supplement 1---source data 1.Source data for the characterization of mutagenized KBM7 cells before selection (control library).**DOI:** [http://dx.doi.org/10.7554/eLife.14601.006](10.7554/eLife.14601.006)10.7554/eLife.14601.007Figure 1---figure supplement 2.Validation of KBM7 loss-of-function screens using anticancer drugs with well-characterized mechanisms of action.(**a--f**) Loss-of-function genetic screens were performed and displayed as described in [Figure 1a](#fig1){ref-type="fig"}. Cells were treated with anticancer drugs at the concentration specified in each panel. Green bubbles represent genes known to be involved in the mechanism of action of the drug tested and the diameter of the bubble is proportional to the number of unique insertion sites in the pooled resistant clones (doxorubicin, *TOP2A*: N = 4; etoposide, *TOP2A*: N = 5; topotecan, *TOP1*: N = 10; bortezomib, *PSMC6*: N = 8; oxaliplatin, *SLC43A2*: N = 5; gemcitabine, *DCK*: N = 161). Genes with a total of less than 50 sequencing reads were not displayed in the bubble plots. (**a**) The screen with doxorubicin uncovered *TOP2A*, which encodes topoisomerase IIA, the direct target of doxorubicin ([@bib56]). (**b**) The screen with etoposide uncovered *TOP2A*, consistent with its known mechanism of action ([@bib40]). (**c**) The screen with topotecan identified its known direct target ([@bib44]), type I topoisomerase (TOP1), as well as *ABCG2*. It is known that *overexpression,* not inactivation, of this transporter causes resistance to topotecan ([@bib38]). In the pooled resistant clones, retroviral integration sites clustered to the beginning of the *ABCG2* transcript and most were actually found upstream of the transcription start site (TSS). A topotecan-resistant clone (ABCG2^GT^) with a retroviral site 400 bp upstream of the TSS of *ABCG2* was isolated and the expression level of *ABCG2* was determined by RT-qPCR (Materials and methods). ABCG2^GT^ displayed a △△C~T~ of 6.2 ± 0.3 compared to KBM7 indicating an increase in ABCG2 mRNA levels of up to 70-fold compared to KBM7 (mean values of three independent experiments ± standard deviation). (**d**) The screen with bortezomib, a proteasome inhibitor ([@bib1]), identified proteasome subunits (*PSMC6*, *PSMD12*, *PSMC5*, *PSMD7*, *PSMD2*). (**e**) The screen with oxaliplatin, a DNA crosslinker, identified *SLC43A2*, a solute carrier that transports neutral amino acids into cells ([@bib12]), suggesting that SLC43A2 facilitates the transport of oxaliplatin into cells consistent with the known role of solute carriers in the transport of anticancer drugs ([@bib37]). (**f**) The screen with gemcitabine, a deoxycytidine analog, identified *DCK* and *CDADC1*. Deficiency of DCK is associated with gemcitabine resistance ([@bib9]) and CDADC1 is a cytidine and dCMP deaminase known to be involved in resistance to deoxycytidine analogs ([@bib16]) ([Figure 1---figure supplement 2---source data 1](#SD3-data){ref-type="supplementary-material"}).**DOI:** [http://dx.doi.org/10.7554/eLife.14601.007](10.7554/eLife.14601.007)10.7554/eLife.14601.008Figure 1---figure supplement 2---source data 1.Source data for anticancer drug loss-of-function KBM7 screens.**DOI:** [http://dx.doi.org/10.7554/eLife.14601.008](10.7554/eLife.14601.008)10.7554/eLife.14601.009Figure 1---figure supplement 3.Loss-of-function genetic screens in KBM7 cells performed at three different concentrations of ophiobolin A (OPA) consistently identify genes in the Kennedy pathway.(**a--c**) Screens were performed and analyzed as in [Figure 1a,](#fig1){ref-type="fig"} at the indicated concentrations of OPA. Each bubble represents a gene and the diameter of the bubble is proportional to the number of unique insertion sites in the pool of resistant clones (for OPA 358 nM, *ETNK1*: N=9; for OPA 365 nM, *ETNK1*: N=10; for OPA 418 nM, *ETNK1*: N=6) ([Figure 1---figure supplement 3---source data 1](#SD4-data){ref-type="supplementary-material"}).**DOI:** [http://dx.doi.org/10.7554/eLife.14601.009](10.7554/eLife.14601.009)10.7554/eLife.14601.010Figure 1---figure supplement 3---source data 1.Source data for additional ophiobolin A (OPA) loss-of-function KBM7 screens.**DOI:** [http://dx.doi.org/10.7554/eLife.14601.010](10.7554/eLife.14601.010)10.7554/eLife.14601.011Figure 1---figure supplement 4.Titration of the toxicity of ophiobolin A (OPA) towards KBM7 wild-type and gene-trapped cell lines, and additional data for complementation assays.(**a**) Viability of wild-type KBM7 (WT), PCYT2^GT^, and ETNK1^GT^ cell lines after treatment with OPA. Cells grown in standard conditions were treated with OPA (or DMSO vehicle) at the indicated concentration for 72 hr. Cell viability was quantified using a commercial luciferase-based assay measuring ATP content and the viability of each vehicle-treated cell line was normalized to 1. (**b**,**c**) Additional characterization of complemented PCYT2^GT^ cells. Constructs expressing either PCYT2 or GFP (control) were delivered to WT or PCYT2^GT^ cells by lentiviral transduction. \'---\' denotes non-transduced cell lines. (**b**) Quantification of relative *PCYT2* mRNA levels by RT-qPCR in cell lines expressing the indicated cDNA, normalized to the level of *PCYT2* mRNA in WT. (**c**) Determination of cellular phosphatidylethanolamine (PE) content in complemented cell lines by total lipid extraction, separation of phospholipids by thin layer chromatography, and quantification of phospholipids by phosphorus content analysis. The PE content of WT was normalized to 100%. (**a**--**c**) Results were obtained from assays performed in triplicate and data represent mean values ± standard deviation.**DOI:** [http://dx.doi.org/10.7554/eLife.14601.011](10.7554/eLife.14601.011)

We isolated and characterized KBM7 clonal cell lines carrying inactivating insertions in the genes *PCYT2* (in first intron) and *ETNK1* (in first exon) (named PCYT2^GT^ and ETNK1^GT^, respectively). As expected, these cell lines had strongly reduced levels (\<2%) of either *PCYT2* or *ETNK1* mRNA, as quantified by RT-qPCR ([Figure 1c](#fig1){ref-type="fig"}) and, consistent with the screening results, both clones were less sensitive to OPA ([Figure 1d](#fig1){ref-type="fig"} and [Figure 1---figure supplement 4a](#fig1s4){ref-type="fig"}). Since human cells can synthesize PE through multiple mechanisms (the two major ones being the Kennedy pathway and decarboxylation of phosphatidylserine in mitochondria; [@bib24]), and it is known that cells employ mechanisms to maintain homeostasis of phospholipid levels ([@bib32]), we tested whether inactivation of the Kennedy pathway in KBM7 cells decreases total cellular PE levels. We extracted total lipids, separated phospholipids by thin layer chromatography, and quantified phospholipids by phosphorus content analysis. Both PCYT2^GT^ and ETNK1^GT^ cell lines showed reduced PE levels compared to KBM7 cells, by 24% and 16%, respectively ([Figure 1e](#fig1){ref-type="fig"}). Since gene-trapping of *PCYT2* renders KBM7 cells slightly more resistant to OPA and reduces PE levels to a larger extent than inactivation of *ETNK1*, our further studies focused on *PCYT2.*

To validate that inactivation of the Kennedy pathway causes OPA resistance, we transduced PCYT2^GT^ cells with a lentiviral construct driving expression of PCYT2 and observed that this complementation rescues OPA sensitivity ([Figure 1f](#fig1){ref-type="fig"}). As expected, both *PCYT2* mRNA levels and total PE content were also restored to wild-type levels in complemented cells ([Figure 1---figure supplement 4b--c](#fig1s4){ref-type="fig"}). We next assessed the generality of our results across cell lines by testing the effect of silencing *PCYT2* in HEK293T cells on viability during OPA treatment. Cells expressing two shRNA (short hairpin RNA) constructs had 85% and 70% reduced *PCYT2* mRNA levels, respectively ([Figure 2a](#fig2){ref-type="fig"}), exhibited increased OPA resistance ([Figure 2b](#fig2){ref-type="fig"}), and had reduced cellular PE levels ([Figure 2c](#fig2){ref-type="fig"}). In summary, these data show that a reduction of the Kennedy pathway activity, and thus PE levels, in human cells leads to an increase in OPA resistance.10.7554/eLife.14601.012Figure 2.Interaction between the activity of the Kennedy pathway and ophiobolin A (OPA) cytotoxicity.(**a--c**) shRNA knockdown of the Kennedy pathway in HEK293T cells leads to increased resistance to OPA toxicity. Constructs enabling stable expression of shRNAs against *PCYT2* (kd1 and kd2), a scrambled shRNA (Scr.), or an empty vector control (Control) were delivered to HEK293T cells by lentiviral transduction. Results were obtained from assays performed on three independent transduced cell lines and data represent mean values ± standard deviation. (**a**) Quantification of relative *PCYT2* mRNA levels by RT-qPCR, normalized to the level of *PCYT2* mRNA in the control. (**b**) Cell viability measurement after 72 hr of treatment with OPA (or DMSO vehicle) using a luciferase-based assay quantifying ATP content. The viability of each vehicle-treated cell line was normalized to 1. (**c**) Determination of cellular phosphatidylethanolamine (PE) levels by total lipid extraction, separation of phospholipids by thin layer chromatography (TLC), and quantification of phospholipids by phosphorus content analysis. PE content is displayed as a percentage of total phospholipids. (**d**) OPA treatment activates the Kennedy pathway and increases PE content in HEK293T and HCT116 cells. Cells were treated with OPA, meclizine, or DMSO vehicle for 5 hr, then ethanolamine \[1,2-^14^C\] was added and the treatment was prolonged for an additional 24 hr. Total phospholipids were extracted and separated by silica gel TLC. PE contents were quantified as in (**c**) and the PE content of vehicle-treated cells was normalized to 100%. ^14^C-PE levels were quantified by liquid scintillation counting of silica scrapings and were normalized to total phospholipid content. Results were obtained from three independent experiments and data represent mean values ± standard error of the mean.**DOI:** [http://dx.doi.org/10.7554/eLife.14601.012](10.7554/eLife.14601.012)

OPA treatment results in activation of the Kennedy pathway in human cells {#s2-3}
-------------------------------------------------------------------------

Having established a clear link between the activity of the Kennedy pathway and the cytotoxicity of OPA, we next investigated the underlying molecular mechanism. There is precedent for small molecules that target the Kennedy pathway: the antihistamine and antiemetic drug meclizine directly inhibits PCYT2, reducing the average flux through the Kennedy pathway ([@bib26]). To explore the possibility that OPA exerts cytotoxicity by inhibiting or activating one of the enzymes in the Kennedy pathway, we measured the activity of the pathway after OPA treatment in the two commonly used human cell lines, HEK293T and HCT116. Cells were treated with OPA (or vehicle) and then incubated with ethanolamine \[1,2-^14^C\], the substrate of the first enzyme in the Kennedy pathway. Interestingly, when either cell line was treated with concentrations of OPA that induced mild cytotoxicity, both the average flux through the Kennedy pathway (measured by accumulation of the radiolabel into PE) and the steady state level of PE were *increased* compared to vehicle-treated cells ([Figure 2d](#fig2){ref-type="fig"}). In contrast, when we treated cells with meclizine we observed the expected decrease in the flux through the pathway and reduced PE content ([Figure 2d](#fig2){ref-type="fig"}). Since the change in enzyme activity induced by OPA treatment is small, we do not believe that OPA acts directly on an enzyme in the Kennedy pathway to cause cytotoxicity.

OPA is inactivated by exogenous PE in cell culture medium {#s2-4}
---------------------------------------------------------

The known reactivity of OPA with primary amines ([@bib8]) and the observation that resistance to OPA toxicity correlates with lower PE content ([Figures 1e](#fig1){ref-type="fig"} and [2c](#fig2){ref-type="fig"}) led us to propose that OPA might directly target PE through covalent modification of its ethanolamine head group. If this hypothesis is correct, adding exogenous PE along with OPA to the growth medium of cells should result in the formation of PE-OPA covalent adducts in the medium. The majority of these adducts should not partition efficiently into cells due to limited aqueous solubility, and thereby adding exogenous PE should reduce the number of OPA molecules available to react with endogenous PE and kill cells. In agreement with this prediction, addition of a commercial preparation of PE to cells treated with a cytotoxic amount of OPA rescued cell viability, whereas addition of the phospholipids phosphatidylcholine (PC) or phosphatidylserine (PS) had no effect ([Figure 3a](#fig3){ref-type="fig"}). PE extracts from diverse sources were all similarly able to rescue cellular viability, suggesting that small quantities of impurities in these preparations are not likely responsible for OPA inactivation ([Figure 3---figure supplement 1a](#fig3s1){ref-type="fig"}). To provide additional evidence that the difference in the effects of PE and PC on OPA toxicity derive solely from differences in the head group (and not differences in fatty acid composition or impurities), we assayed a pair of commercial lipid preparations: one that consists of an extract of PC, and an identical PC extract in which the choline head group of PC has been exchanged for ethanolamine to yield a transphosphatidylated PE extract. When tested in the OPA inactivation assays, transphosphatidylated PE rescued cell viability whereas PC did not, substantiating the claim that PE is the molecule responsible for OPA inactivation ([Figure 3---figure supplement 1a](#fig3s1){ref-type="fig"}). In addition, we observed that constituents of the head group of PE, ethanolamine and *O*-phosphorylethanolamine, could inactivate OPA, although much less potently than PE, and that triethanolamine (lacking a primary amine) had no effect ([Figure 3b](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1b](#fig3s1){ref-type="fig"}).10.7554/eLife.14601.013Figure 3.Ophiobolin A (OPA) reacts with the ethanolamine (Etn) head group of phosphatidylethanolamine (PE) via a Paal-Knorr reaction.(**a**) Exogenous PE, but not phosphatidylcholine (PC) or phosphatidylserine (PS), added to growth medium quenches the cytotoxicity of OPA. Commercially available phospholipids extracted from chicken egg (PE and PC) or bovine brain (PS) (or vehicle) were added to 20 ng/μL (\~25 μM) to the growth medium of HEK293T cells. Cells were subsequently treated with OPA (or DMSO vehicle) for 72 hr and cell viability was then quantified using a luciferase-based assay measuring ATP content. The viability of vehicle-treated cells in the absence of OPA was normalized to 1. (**b**) The primary amine of Etn is essential for OPA inactivation. A cell viability assay was performed as in (**a**) with Etn, *O*-phosphorylethanolamine (Phospho-Etn) and triethanolamine (Trietn). Only viabilities in 300 nM OPA are displayed and the viability of vehicle-treated cells in 300 nM OPA was normalized to 100%. Full plots are available in [Figure 3---figure supplement 1b](#fig3s1){ref-type="fig"}. (**c**) OPA was incubated with an excess of Etn (or ethanol control) in aqueous buffer. HEK293T cells grown in standard conditions were treated with the reaction product for 72 hr and cell viability was then quantified using a luciferase-based assay measuring ATP content. (**a--c**) Results were obtained from assays performed in triplicate and data represent mean values ± standard deviation. (**d**) Liquid chromatography-mass spectrometry (LC-MS) analysis in positive ion mode of the in vitro reaction of OPA (exact mass = 400.2614) with Etn (exact mass = 61.0528) shows formation of a single product at an m/z corresponding to an addition reaction minus two molecules of H~2~O. Both OPA and Etn were used as reactant controls and the total ion chromatograms of the three samples are displayed overlaid. The m/z of the most abundant ion is displayed above corresponding peaks. (**e**) OPA reacts with Etn to form a pyrrole-containing product detectable using Ehrlich\'s reagent. An in vitro reaction of OPA with Etn was mixed with Ehrlich\'s reagent and the absorbance of the resulting solution was measured between 450 and 700 nm. Reactions with DMSO (vehicle) instead of OPA and Trietn instead of Etn were used as negative controls. (**f**) Proposed reaction between PE and OPA.**DOI:** [http://dx.doi.org/10.7554/eLife.14601.013](10.7554/eLife.14601.013)10.7554/eLife.14601.014Figure 3---figure supplement 1.Additional data for ophiobolin A (OPA) inactivation assays with exogenously added small molecules.(**a**) Commercially available phospholipids (or vehicle) were added at 20 or 40 ng/μL (\~25 or 50 μM) to the growth medium of HEK293T cells. Cells were subsequently treated with OPA (or DMSO vehicle) for 72 hr and cell viability was then quantified using a luciferase-based assay measuring ATP content. The viability of vehicle-treated cells in the absence of OPA was normalized to 1. For clarity, only cell viability data in the presence of OPA are displayed. (**b**) Full plots of the data displayed in [Figure 3b](#fig3){ref-type="fig"}. The viability of vehicle-treated cells in the absence of OPA was normalized to 1.0. (**c**) Assay performed as in (**a**) using synthetic DOPC (dioleoyl-PC), DOPE (dioleoyl-PE), and DOPS (dioleoyl-PS). (**d**) Assay performed as in [Figure 3b](#fig3){ref-type="fig"}, but using ethanolamine and serine. (**e**) OPA inactivation assays with 1,4-dicarbonyl scavengers, lysine, and ethanolamine. Assays were performed and displayed in a similar way as in (**b**) except that the exogenous molecules were preincubated with OPA in phosphate-buffered saline at 5× their final concentration for 2.5 hr before adding to the growth medium of HEK293T cells. (**a**--**e**) Results were obtained from assays performed in triplicate and data represent mean values ± standard deviation.**DOI:** [http://dx.doi.org/10.7554/eLife.14601.014](10.7554/eLife.14601.014)10.7554/eLife.14601.015Figure 3---figure supplement 2.Proposed mechanism of covalent modification of phosphatidylethanolamine (PE) by ophiobolin A (OPA) through a Paal-Knorr-like reaction pathway ([@bib10]; [@bib7], [@bib5]).Addition of the amino group of PE onto the aldehyde moiety of OPA leads to formation of a hemiaminal. Based on the mechanism of the Paal-Knorr reaction and the specific reactivity of OPA, the reaction between PE and OPA is believed to proceed through two potential mechanisms: (i) elimination of a water molecule leading to formation of an imine and subsequent rearrangement to an enamine. Cyclization of the enamine followed by dehydration yields the final pyrrole-containing adduct. (ii) Cyclization of the hemiaminal leads to formation of a dihydroxypyrrolidine. A double elimination of water and double bond shift leads to the final pyrrole-containing adduct. In studies involving the formation of pyrrole adducts from the reaction of 4-oxohexanal and a primary amine, the reaction is known to proceed through the mechanism involving cyclization of the hemiaminal ([@bib5]). Under certain conditions, pyrrole adducts are known to be oxidized and the two main expected products are the lactam and hydroxylactam derivatives ([@bib55]). In addition, OPA contains an unsaturated aldehyde moiety which is known to readily react with thiols in a Michael addition reaction ([@bib27]). 4-Oxo-2-nonenal, a product of cellular lipid oxidation which has similar reactive functionalities as OPA, has been shown to readily react with *N*-acetylcysteine ([@bib6]). Interestingly, initial Michael adduct formation of OPA with a thiol would not prevent a subsequent Paal-Knorr reaction with PE and furthermore these two sequential reactions could lead to protein-lipid crosslinking, a potential cause of cytotoxicity.**DOI:** [http://dx.doi.org/10.7554/eLife.14601.015](10.7554/eLife.14601.015)

The serine head group of PS also contains a primary amine that could react with OPA. However, we observed no inactivation of OPA using either a natural extract of PS ([Figure 3a](#fig3){ref-type="fig"}) or synthetic dioleoyl-PS ([Figure 3---figure supplement 1c](#fig3s1){ref-type="fig"}). In contrast to ethanolamine, adding serine to the growth medium of cells does not lead to OPA inactivation, suggesting that the primary amine in the serine head group is less reactive with OPA than that in the ethanolamine head group ([Figure 3---figure supplement 1d](#fig3s1){ref-type="fig"}). This observation is consistent with previous reports of inefficient adduct formation between PS and reactive aldehydes from fatty acid peroxidation ([@bib29], [@bib28]). In conclusion, these results suggest that OPA is specifically inactivated by PE via reaction with the primary amine on its head group.

OPA reacts with ethanolamine in vitro and forms a pyrrole-containing covalent adduct {#s2-5}
------------------------------------------------------------------------------------

Synthetic studies exploring the chemical reactivity of OPA have shown that OPA can react with primary amines in a Paal-Knorr reaction to yield pyrrole-containing adducts ([@bib20]). To test the hypothesis that OPA also reacts with PE through its primary amine, we explored the product of the reaction between OPA and ethanolamine. Incubation of OPA with an excess of ethanolamine abolished cytotoxicity and analysis by LC-MS/MS revealed that the main product of this reaction is consistent with formation of a covalent adduct with two dehydration reactions ([Figure 3c--d](#fig3){ref-type="fig"}). Incubation of the reaction product of OPA and ethanolamine with Ehrlich\'s reagent ([@bib3]) yielded a purple solution (A~max~ = 580 nm), characteristic of pyrroles ([Figure 3e](#fig3){ref-type="fig"}). Addition of salicylamine and pentyl-pyridoxamine, potent scavengers of 1,4-dicarbonyls, to OPA led to its inactivation at concentrations 30- and 300-fold lower than for ethanolamine, consistent with the known kinetics of these scavengers in Paal-Knorr reactions ([@bib3], [@bib4]) ([Figure 3---figure supplement 1e](#fig3s1){ref-type="fig"}). These findings, together with the results from the OPA inactivation assays, are consistent with OPA reacting with PE according to a Paal-Knorr reaction mechanism ([Figure 3f](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}).

OPA reacts with PE in vitro and in human cells {#s2-6}
----------------------------------------------

Based on our observations that OPA can be inactivated by exogenous PE in vitro and that it forms a pyrrole-containing adduct with ethanolamine, we hypothesize that the bioactivity of OPA arises from the formation of covalent adducts with PE. To facilitate detection of such adducts in human cells after treatment with OPA, we utilized phospholipase D (PLD) from *Streptomyces chromofuscus *([@bib55]) to release modified PE head groups from heterogeneous populations of lipids differing in fatty acid composition ([Figure 4a](#fig4){ref-type="fig"}). We first confirmed the efficacy of this approach by synthesizing PE-OPA covalent adducts in vitro and hydrolyzing these adducts with PLD to release ethanolamine-OPA (Etn-OPA) ([Figure 4b](#fig4){ref-type="fig"}). Etn-OPA was unequivocally characterized by its exact mass, retention time, and MS/MS fragmentation pattern using the reaction product of OPA with ethanolamine as a standard ([Figure 3d](#fig3){ref-type="fig"}). The detection of Etn-OPA was dependent on the presence of PE and OPA, and PLD treatment, demonstrating that OPA forms a pyrrole-containing covalent adduct with PE which PLD is able to hydrolyze into Etn-OPA ([Figure 4b](#fig4){ref-type="fig"}).10.7554/eLife.14601.016Figure 4.Ophiobolin A (OPA) forms a pyrrole-containing covalent adduct with phosphatidylethanolamine (PE) in human cells.(**a**) Formation of PE-OPA adducts was detected by measuring the abundance of ethanolamine-OPA (Etn-OPA) after hydrolysis by phospholipase D from *Streptomyces chromofuscus* (PLD). (**b**) Extracted ion chromatograms (m/z = 426.2982--426.3024) of the liquid chromatography-mass spectrometry (LC-MS) analysis of in vitro reactions of PE with OPA and subsequent digestion with PLD. Control reactions include systematic replacement of each reagent by vehicle and replacement of PE with phosphatidylcholine (PC). (**c--d**) Extracted ion chromatograms (m/z = 426.2982--426.3024) showing the detection of PE-OPA adducts in lipids extracted from cells treated with OPA. (**c**) HEK293T cells grown in standard conditions were incubated with 250 nM OPA for 24 hr. Total cellular lipids were extracted in the presence of pentyl-pyridoxamine to quench unreacted OPA. Lipids were incubated with PLD and analyzed by LC-MS for the presence of Etn-OPA. Negative controls include replacement of OPA by DMSO vehicle or absence of PLD treatment. (**d**) Same as (**c**) but for HCT116 cells treated with 450 nM OPA. Full chromatograms and replicate experiments are available in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.14601.016](10.7554/eLife.14601.016)10.7554/eLife.14601.017Figure 4---figure supplement 1.Raw data and replicate experiment for data represented in [Figure 4c--d](#fig4){ref-type="fig"}.Extracted ion chromatograms (m/z = 426.2982--426.3024) showing the detection of phosphatidylethanolamine-ophiobolin A (PE-OPA) adducts in lipids extracted from cells treated with OPA. (**a**) HEK293T cells grown in standard conditions were incubated with 250 nM OPA for 24 hr. Total cellular lipids were extracted in the presence of pentyl-pyridoxamine to quench unreacted OPA and prevent any post-lysis reaction. Lipids were then incubated with phospholipase D (PLD) and analyzed by LC-MS for presence of Etn-OPA. Negative controls include replacement of OPA by DMSO vehicle (- OPA) or absence of PLD treatment (- PLD). (**b**) Same as (**a**) but for HCT116 cells treated with 450 nM OPA. Extracted ion intensity levels (\'NL\') were normalized to the peak of highest intensity.**DOI:** [http://dx.doi.org/10.7554/eLife.14601.017](10.7554/eLife.14601.017)10.7554/eLife.14601.018Figure 4---figure supplement 2.Higher-energy collisional dissociation (HCD) MS/MS fragmentation spectra of ethanolamine-ophiobolin A (Etn-OPA).(**a--c**) Etn-OPA was unequivocally characterized by its exact mass, liquid chromatography retention time, and MS/MS fragmentation pattern. Ions at m/z = 426.30 and at a retention time of 12.5 min were fragmented by collision-induced dissociation to ensure an MS/MS spectrum consistent with that of Etn-OPA prepared by incubation of OPA with ethanolamine. \[M+H\]^+^ ions were targeted using dynamic exclusion at a normalized collision energy of 35 eV. (**a**) HCD spectrum of ion at m/z = 426.30 and at a retention time of 12.5 min in the experiment in [Figure 3d](#fig3){ref-type="fig"} involving in vitro reaction of OPA with ethanolamine. (**b**) HCD spectrum of ion at m/z = 426.30 and at a retention time of 12.5 min in the experiment in [Figure 4b](#fig4){ref-type="fig"} involving in vitro reaction of OPA with phosphatidylethanolamine (PE) and hydrolysis with phospholipase D (PLD). (**c**) HCD spectrum of ions at m/z = 426.30 and at a retention time of 12.5 min in the experiments in [Figure 4c--d](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} involving PLD hydrolysis of phospholipids extracted from cells treated with OPA.**DOI:** [http://dx.doi.org/10.7554/eLife.14601.018](10.7554/eLife.14601.018)

We next used this analytical strategy to query the presence of PE-OPA adducts in the pool of phospholipids extracted from human cells treated with OPA. HEK293T and HCT116 cells were treated, total cellular phospholipids were extracted, and residual OPA was rapidly quenched with pentyl-pyridoxamine to prevent any reaction of PE with residual OPA after cell lysis ([@bib6]). The quenched extracted phospholipids were digested with PLD and analyzed by LC-MS/MS, which revealed the presence of Etn-OPA dependent on OPA and PLD treatment ([Figure 4c--d](#fig4){ref-type="fig"} and [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"} and [2](#fig4s2){ref-type="fig"}). Importantly, the absence of Etn-OPA in the control lacking PLD treatment indicates that OPA does not react with cellular ethanolamine ([Figure 4c--d](#fig4){ref-type="fig"}). These findings demonstrate that OPA forms pyrrole-containing covalent adducts with PE in human cells.

OPA induces membrane leakiness {#s2-7}
------------------------------

Modification of PE to PE-OPA adducts substantially changes the biophysical properties of PE by modifying its head group from small and polar to bulky and hydrophobic. We thus hypothesized that PE-OPA adduct formation could lead to destabilization of cellular lipid bilayers and be the main cause of OPA cytotoxicity. To determine whether OPA induces membrane leakiness due to adduct formation, we used artificial liposomes whose PE content we could modulate. We prepared large unilamellar lipid vesicles (LUVs) composed of a variable ratio of dioleoyl-PE to dioleoyl-PC and loaded with the fluorescent probe calcein ([@bib2]; [@bib61]). As calcein fluorescence becomes dequenched upon release from LUVs, an increase in fluorescence can be used as an indicator of liposome leakage. We observed that OPA treatment caused extensive liposome leakage, and that the extent of leakage is directly dependent on both the PE content of the liposomes and on the OPA concentration ([Figure 5a](#fig5){ref-type="fig"}). Importantly, we observed that liposomes composed only of PC or with very low PE content remain intact even at high OPA concentration, indicating that the leakage is likely specifically due to the formation of PE-OPA adducts. These results clearly show that OPA destabilizes lipid bilayers, supporting our hypothesis that membrane permeabilization is the main cause of OPA cytotoxicity.10.7554/eLife.14601.019Figure 5.Ophiobolin A (OPA) induces leakage from liposomes.(**a**) Effect of 60 min OPA treatment on the leakage of the fluorescent dye calcein from artificial liposomes composed of various ratios of phosphatidylethanolamine (PE) to phosphatidylcholine (PC). Large unilamellar vesicles (LUVs) composed of dioleoyl-PE and dioleoyl-PC, and encapsulating calcein were prepared by extrusion. Leakage assays were initiated by addition of OPA and were monitored by quantification of the fluorescence of calcein, which dequenches upon release from liposomes. OPA-induced liposome leakage was determined by normalization of fluorescence to a DMSO vehicle control (0% leakage) and to detergent-treated liposomes (100% leakage). Results were obtained from assays performed in triplicate and data represent mean values ± standard error of the mean. Inset plots display examples of the kinetics of leakage after OPA addition for two liposome preparations. (**b**) Proposed model of the mechanism of action of OPA in human cells. When applied to cells, OPA accumulates in the phospholipid bilayer of the plasma membrane as it is a lipophilic compound. Due to high local concentrations or the hydrophobic environment (or both), OPA efficiently reacts with the primary amine head group of phosphatidylethanolamine (PE) in a Paal-Knorr-like reaction. Formation of PE-OPA adducts changes the biophysical properties of PE by modifying its head group from small and polar to bulky and hydrophobic, leading to membrane permeabilization and ultimately cell death.**DOI:** [http://dx.doi.org/10.7554/eLife.14601.019](10.7554/eLife.14601.019)

Discussion {#s3}
==========

Our work illustrates the utility of loss-of-function screens in human cells to identify genes involved in the MOA of promising anticancer compounds such as OPA. The Kennedy pathway genes identified in the screen of OPA led to the identification of a phospholipid molecule as the cellular target of OPA. This discovery was possible due to the unbiased nature of the screen and would have been difficult to achieve using alternative methods such as affinity chromatography followed by mass spectrometry. Few studies have yet taken advantage of the recent development of novel genetic tools in human cells to identify the target of small molecules, and this is the first study to uncover a non-protein based target ([@bib42]). Here we show that OPA forms a pyrrole-containing covalent adduct with PE in human cells. Reduction of PE levels through inactivation of the Kennedy pathway results in a reduction in OPA cytotoxicity. We also show that PE-OPA adduct formation leads to destabilization of lipid bilayers in vitro. Collectively, this study indicates that PE is the main target of OPA in human cells and leads to the hypothesis that formation of PE-OPA adducts directly causes the observed cytotoxicity of OPA through membrane destabilization ([Figure 5b](#fig5){ref-type="fig"}).

OPA is reactive towards primary amines, but the chemical reactivity of PE alone does not explain why OPA would selectively react with PE over ethanolamine, lysine side chains of proteins, or any other abundant primary amine in human cells ([@bib20]). While we cannot exclude the possibility that covalent modification of cellular proteins contributes to the observed toxicity of OPA, our experimental results show that the concentration of PE required to inactivate OPA in vitro is at least 2000-fold lower than that of ethanolamine or lysine ([Figure 3a](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). This selectivity may arise because, at the concentrations tested, ethanolamine and lysine are freely soluble in aqueous buffers whereas PE forms insoluble lipid aggregates. Considering the lipophilic nature of OPA, it is likely that OPA accumulates in the lipid aggregates and efficiently reacts with PE due to high local concentrations or to the hydrophobic environment, or both. In a comparable way, we believe that the selectivity in living cells is the result of accumulation of OPA in lipid bilayers and efficient reaction with PE, the most abundant primary amine in human lipid bilayers ([@bib58]). The observation that OPA does not react with ethanolamine in human cells, despite efficient reaction with PE, supports this claim ([Figure 4c--d](#fig4){ref-type="fig"}).

The increase in OPA resistance conferred by inactivation of the Kennedy pathway in our haploid genetic screen strongly suggests that PE-OPA covalent adduct formation is a major determinant of OPA cytotoxicity. We surmise that the observed cytotoxicity of OPA reflects the amount of covalent PE-OPA adducts formed in cells, which, based on the mechanism of the Paal-Knorr reaction, should be dependent on the concentrations of both OPA and PE. Accordingly, we observed that a mild reduction in PE levels (16--24%) was accompanied by a mild increase in OPA resistance (IC~50~ from 43 nM in wild-type cells to 70--85 nM in the mutants) ([Figure 1e](#fig1){ref-type="fig"} and [Figure 1---figure supplement 4a](#fig1s4){ref-type="fig"}). As the amplitude of changes in the observed cytotoxicity of OPA can be accounted for by changes in PE levels, we believe that PE represents the main target of OPA in human cells.

Several members of the ophiobolin family of fungal metabolites have been isolated and evaluated for cytotoxicity in a panel of human cell lines ([@bib8]; [@bib20]). Notably, the C-6 epimer of OPA (6-*epi*-OPA) is 40-fold less cytotoxic than OPA ([@bib20]), although both compounds would form the same pyrrole adduct upon reaction with PE, as the stereocenter at position 6 is lost with pyrrole formation. This observation must mean that the reaction of PE with 6-*epi*-OPA is on the order of 40-fold slower than the reaction of PE with OPA. The ring cyclization step is the rate limiting step of the Paal-Knorr reaction ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) and this step is strongly influenced by the stereochemistry of the 1,4 diketone; rates of pyrrole formation can be up to 57-fold different between stereoisomers ([@bib7]). Thus, the 40-fold difference in potency between OPA and 6-*epi*-OPA can likely be attributed to differences in the rate of pyrrole adduct formation, and this observation supports our model that cytotoxicity depends on the amount of PE-OPA adduct formed.

We hypothesize that formation of PE-OPA adducts disrupts the lipid bilayer of human cells to induce cell death. As seen in the LUVs leakage experiments, OPA induces strong membrane permeabilization in model membranes and the extent of permeabilization is dependent on PE content ([Figure 5a](#fig5){ref-type="fig"}). Interestingly, this observation is consistent with our expectation that the rate of adduct formation is dependent on PE content and suggests that OPA might display higher potency against cells or tissues containing high PE contents. Also, the dependence of membrane leakiness on PE content provides a mechanistic basis for our observation that Kennedy pathway KBM7 mutants are resistant to OPA due to lower PE levels. Cytotoxicity through modification of PE has previously been reported for polygodial, a 1,4-dialdehyde antifungal compound, which has been shown to form a pyrrole-containing adduct with PE on the cell surface that is directly linked to its antifungal activity ([@bib23]). Furthermore, it has been previously shown that covalent modification of PE with isoketals alters membrane curvature because the newly formed bulky hydrophobic head group partitions to the lipid bilayer and increases lateral pressure ([@bib30]). We believe such a mechanism may contribute to the ability of PE-OPA adducts to disrupt lipid bilayers, and suspect that the extent of lipid bilayer destabilization is highest in the plasma membrane as it is the first source of PE encountered by OPA.

We were initially surprised to find that treatment of human cells with OPA led to activation of the Kennedy pathway and an increase in PE content ([Figure 2d](#fig2){ref-type="fig"}). However, phospholipid homeostasis in mammalian cells is not well understood, but it is generally accepted that mechanisms are in place to tightly regulate membrane lipid composition ([@bib32]). The activation of the pathway seen upon OPA treatment may be a cellular response to the formation of PE-OPA adducts due to mechanisms regulating membrane PE homeostasis.

In addition to its activity in human cells, OPA is cytotoxic towards a broad range of organisms ([@bib8]). Early studies on the mechanism of cytotoxicity of OPA in plant cells suggested that it causes non-specific damage to membranes ([@bib19]) or even \"covalent modification of some membrane component\" ([@bib57]). Considering our work in human cells and the fact that PE is ubiquitously found in nature ([@bib58]), PE may be the main target of OPA in plants and potentially other organisms.

OPA has been shown to have an antitumor effect in a mouse glioblastoma model ([@bib14]; [@bib20]). The basis for the tumor selectivity of OPA may be due to altered distribution or higher abundance of PE in cancer cells. Indeed, it has recently been shown that PE is found in higher quantities on the outer leaflet of cancer cells ([@bib54]). Furthermore, host defense peptides have been shown to display selectively against cancer cells based on the difference in surface phospholipid composition compared to normal cells ([@bib35]; [@bib46]). Using the changes in lipid composition of cancer cells as a biomarker represents an interesting approach to chemotherapeutics development ([@bib35]) and our findings raise the exciting possibility that OPA will prove an effective chemotherapy tool for multidrug-resistant glioblastoma.

Materials and methods {#s4}
=====================

Chemical reagents {#s4-1}
-----------------

Unless otherwise mentioned, all chemicals were from Sigma-Aldrich (St Louis, MO). Ophiobolin A (\>95%) was from Enzo Life Sciences (Farmingdale, NY). Gemcitabine, oxaliplatin, bortezomib, topotecan, and doxorubicin were from LC Laboratories (Woburn, MA). Ethanolamine \[1,2-^14^C\] HCl was from American Radiolabeled Chemicals (St Louis, MO). Phospholipids were from Sigma-Aldrich (PE, chicken egg; PC, chicken egg; PS, bovine brain) and from Avanti Polar Lipids (Alabaster, AL) (transphosphatidylated PE, chicken egg; PE, porcine brain; DOPE; DOPC; DOPS). Salicylamine and pentyl-pyridoxamine were a kind gift of V. Amarnath (Vanderbilt) ([@bib3], [@bib4]). Stock solutions, unless otherwise mentioned, were prepared in DMSO (99.9%) at 500× concentration to yield a final concentration of 0.2% DMSO.

Cell culture {#s4-2}
------------

KBM7 cells were obtained from Thijn Brummelkamp ([@bib17], [@bib18]) and were cultured at 37°C in 5% CO~2~ in Iscove\'s Modified Dulbecco Medium (IMDM) (Gibco, Thermo Fisher Scientific, Waltham, MA) supplemented with 10% heat inactivated fetal bovine serum (Gibco), and penicillin/streptomycin at final concentrations of 100 U/mL and 100 μg/mL, respectively (P/S) (Corning Inc., Corning, NY). HEK293T and HCT116 were obtained from ATCC (Manassas, VA). HEK293T were cultured at 37°C in 5% CO~2~ in Dulbecco's Modified Eagle Medium (DMEM) (ATCC) supplemented with 10% fetal bovine serum (FBS) (ATCC), and P/S. HCT116 were cultured at 37°C in 5% CO~2~ in McCoy\'s 5A (ATCC) supplemented with 10% FBS, and P/S. Cell lines were used at low passage numbers from primary stocks and were not further authenticated or tested for mycoplasma.

Haploid genetic screens in KBM7 cells {#s4-3}
-------------------------------------

Mutagenized KBM7 cells were prepared as in [@bib11]. For each screen, 100 million cells were diluted in 200 mL growth medium and the small molecule of interest was added from a 500× stock solution in DMSO. Then 100,000 cells per well were aliquoted in 96-well plates. Plates were incubated at 37°C in 5% CO~2~ until colonies were visible (about 3 weeks). All resistant cells were pooled, washed with Dulbecco\'s phosphate buffer saline (PBS) and genomic DNA was prepared from 30 million cells using the QIAamp DNA mini kit (Qiagen, Hilden, Germany). Genomic DNA was first digested in separate reactions with NlaIII and MseI and then self-ligated under dilute conditions using T4 DNA ligase (New England Biolabs, Ipswich, MA). After clean-up of the reactions using the MiniElute PCR purification kit (Qiagen), self-ligated products were amplified in a PCR reaction using 10 μM LTRSolexaI, 1 μM either NlaIII or MseI adaptor (depending on the enzyme used for DNA digestion), and 10 μM of index primer, and using Phusion Hot Start Flex polymerase (New England Biolabs). PCR products were cleaned up using the MiniElute PCR purification kit and the presence of amplified products was verified by agarose gel electrophoresis. The PCR reactions of up to 20 screens with unique barcodes were pooled and sequenced using Illumina\'s (San Diego, CA) HiSeq 2500 platform (50 bp, single read) and using primer SolexaSeqFlank. About 5--10 million reads were obtained for each screen.

Reads containing MseI or NlaIII sites flanked by vector DNA sequence were trimmed after the restriction site (to allow potential alignment of fragments shorter than 50 bp). Using Bowtie ([@bib33]), reads were aligned to the human genome hg19 with no mismatch allowed and a single alignment site. A list of unique genomic alignment sites was compiled and sites separated by only 1 or 2 bp were discarded. Additionally, alignment sites represented by only one sequencing read were discarded. The insertion sites were next compared to a list of all annotated human introns and exons (Roche Nimblegen Exon-Intron table, July 2010, hg19). For each human gene, the total number of unique insertions in exonic regions and those in intronic regions in the sense orientation were counted. Finally, an enrichment p-value was calculated using Fisher\'s exact test for each annotated gene by comparing the number of inactivating insertion sites after selection to the number of inactivating insertions in that gene in a control library. Genes with less than 10 total reads were not displayed in the bubble plots.

A control library was prepared by extraction of genomic DNA from mutagenized KBM7 cells collected prior to initiating loss-of-function screens. PCR products were prepared and analyzed in the same way as above except that genomic DNA from a total of 5 million cells was used as template and 35 million sequencing reads were obtained.

Identification and preparation of clonal gene-trapped KBM7 cell lines {#s4-4}
---------------------------------------------------------------------

Drug-resistant cell lines were isolated from loss-of-function KBM7 screens from wells containing single colonies. Cell lines with retroviral insertions in genes of interest were identified by screening for altered gene expression by RT-qPCR (see below). To ensure clonality of the gene-trapped cell lines for subsequent experiments, single colonies were isolated by serial dilution and propagated in standard growth medium. The location of the retroviral insertion sites in the clonal cell lines was identified using a similar strategy as in haploid screens except that the PCR products were sequenced by Sanger sequencing using primer CCseq.

RT-qPCR assay {#s4-5}
-------------

HEK293T or KBM7 cells were grown in 24-well plates and total RNA was extracted from 2 million cells using the RNeasy kit (Qiagen). cDNA was synthesized from 0.5 μg total RNA using Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA) and oligo(dT)~20~ primers (Invitrogen), following the manufacturer\'s instructions. Reactions were diluted two-fold with H~2~O and 10 μL qPCR reactions were set up using 2× SYBR Green PCR Master mix (Thermo Fisher Scientific), 2 μL diluted cDNA preparation, and 0.2 μM of primers. Reactions were monitored using the Stratagene MX3000P qPCR system (Agilent, Santa Clara, CA). Primer pairs CC085/CC086 and CC097/CC098 were used for quantification of *ETNK1* expression levels. Primer pairs CC089/CC090 and CC133/CC134 were used for quantification of *PCYT2* expression levels. Primer pairs CC042/CC043 and CC044/CC045 were used for quantification of *ABCG2* expression levels. Primer pair GAPDH7-8f/GAPDH7-8r was used for quantification of *GAPDH* expression levels. Relative expression levels were quantified by the △△C~T~ method using *GAPDH* as reference gene. Values reported are the average △△C~T~ values calculated with the two primer pairs used. All measurements were performed in triplicate for each primer pair.

Cell viability measurement {#s4-6}
--------------------------

For KBM7 cell lines, 2000 cells were seeded per well in a 96-well plate in 90 μL growth medium. OPA was diluted in 10 μL growth medium and added to wells. After 72 hr incubation at 37°C and 5% CO~2~, 100 μL of CellTiter-Glo reagent (Promega, Madison, WI) was added to each well. After homogenization, 100 μL of the resulting solution was transferred to a black opaque 96-well plate and luminescence was recorded on a Perkin Elmer (Waltham, MA) TopCount NXT system.

For HEK293T cell lines, cultures were grown to 80--90% confluence. Cell lines were subsequently seeded in wells of a 96-well plate at a dilution of 1:75 in 90 μL medium. After 16--18 hr incubation at 37°C and 5% CO~2~, the remaining steps of the assay were performed as described above.

Quantification of PE levels {#s4-7}
---------------------------

Cells were washed with Tris buffer saline (TBS) (20 mM Tris, 150 mM NaCl, pH 7.6) and total lipids were extracted using the Folch method ([@bib22]). Briefly, cells were resuspended in 20 vol of CHCl~3~/MeOH 2:1 (v/v), homogenized for 20 min at room temperature and extracted using 4 vol of NaCl 0.9%. After drying the lower phase using a stream of nitrogen, lipids were resuspended in 2 vol of CHCl~3~/MeOH 2:1 (v/v) and separated on Silica Gel 60 thin layer chromatography (TLC) plates (EMD Millipore, Darmstadt, Germany) according to the method of Skipski et al. ([@bib52]). Plates were developed using CHCl~3~/MeOH/AcOH/H~2~O (50:30:8:3, v/v/v/v). Phospholipids were visualized by iodine staining and their identity was determined using standards. Phospholipids were then quantified by phosphate determination on scraped silica gel spots using the \'micro\' assay as described by [@bib62]. For each experiment, the spot corresponding to PE was scraped into a tube. All other spots in the lane visualized by iodine staining were scraped into a second tube. The quantity of phosphate (P~i~) in each sample was determined using standards consisting of known amounts of KH~2~PO~4~. The relative cellular PE content was estimated using the following formula: PE content = Quantity of P~i~ in PE tube/(Quantity of P~i~ in PE tube + Quantity of P~i~ in tube containing all other phospholipids).

Complementation of KBM7 cell lines {#s4-8}
----------------------------------

PCYT2 was re-expressed in PCYT2^GT^ cells using the lentiviral vector pLJM1 ([@bib48]). cDNA encoding PCYT2 was amplified by PCR from cDNA prepared from total HEK293T RNA using primers CC109 and CC110. The plasmid Flag pLJM1 RagB wt (Addgene \#19313) was digested with SalI and EcoRV. Amplified PCYT2 cDNA was inserted into pLJM1 by Gibson assembly and the constructed plasmid propagated in stbl2 cells (Invitrogen). Plasmid pLJM1-EGFP (Addgene \#19319) was used as a negative control.

Lentivirus was produced in HEK293T cells using pLJM1-based vectors together with packaging vector psPAX2 (Addgene \#12260) and envelope vector pCMV-VSV-G (Addgene \#8454). KBM7 cell lines were infected with lentiviral particles in the presence of 8 μg/mL polybrene and selected in 0.4 μg/mL puromycin for 6 days. Transduced cell lines were maintained in growth medium supplemented with 0.3 μg/mL puromycin during subsequent assays.

Knockdown of *PCYT2* in HEK293T cells {#s4-9}
-------------------------------------

Constructs expressing shRNAs targeting PCYT2 were based on pLKO.1-TRC (Addgene \#10878) ([@bib39]). Five independent shRNAs (TRCN0000236037, TRCN0000035648, TRCN0000236039, TRCN0000236038, TRCN0000236040) designed by the RNAi consortium (Broad Institute) were used to construct HEK293T knockdown cell lines as described by Addgene. Briefly, shRNA oligos were cloned into pLKO.1-TRC and the constructed plasmids were transfected into HEK293T cells together with psPAX2 and pCMV-VSV-G to produce lentivirus. HEK293T cells were then infected with lentiviral particles and selected in 2.0 μg/mL puromycin for 6 days. Cell lines stably expressing shRNAs of interest were maintained in growth medium supplemented with 1.5 μg/mL puromycin during subsequent assays. Scrambled shRNA in pLKO.1 (Addgene \#1864) and empty vector pLKO.1-TRC were used as negative controls. The two shRNA sequences that achieved the highest knockdown efficiency were: kd1 (TCACGGCAAGACAGAAATTAT, TRCN0000035648) and kd2 (ACTAGAGACCCTGGACAAATA, TRCN0000236039).

Kennedy pathway activity measurements {#s4-10}
-------------------------------------

HEK293T and HCT116 cells were grown to 30--40% confluence in 100 mm dishes in 20 mL medium. OPA or meclizine dihydrochloride (\>97%) was diluted to 500 μL in growth medium and added to the dishes. After 5 hr incubation at 37°C and 5% CO~2~, 0.5 μCi ethanolamine \[1,2-^14^C\] was added to each dish and cells were incubated for an additional 24 hr. Cellular PE content was quantified as described above. For determination of \[^14^C\]-PE levels, phospholipids were separated by TLC as described above. After iodine staining, silica spots corresponding to PE were scraped into scintillation vials containing 5 mL of Ready-Solv HP scintillation cocktail (Beckman Coulter, Brea, CA) and \[^14^C\] counts per minute were measured on a Beckman Coulter LS 6500 system. Levels of \[^14^C\]-PE were normalized to the total amount of phospholipids in each sample determined by phosphate determination.

Cell viability assay in presence of exogenous molecules {#s4-11}
-------------------------------------------------------

This assay was performed as the cell viability assay described above with the following modifications. HEK293T cells were seeded in 96-well plates at a dilution of 1:75 in 80 μL medium. Phospholipids were prepared from 5 or 10 mg/mL stocks in CHCl~3~ and were first diluted fivefold in MeOH and then fivefold in growth medium. Organic solvents were degassed at 37°C and 10 μL was added to the wells. OPA was diluted in 10 μL growth medium and added to the wells. The rest of the assay was performed as above. Ethanolamine, triethanolamine, *O*-phosphorylethanolamine, and serine were prepared as 1 M solutions in H~2~O, adjusted to pH 7 with HCl or NaOH, and diluted with H~2~O in order to prepare 20 stock solutions. These solutions were diluted to 10 μL with growth medium and added to the wells. For experiments with scavengers of 1,4-dicarbonyls, lysine·HCl was prepared as a 1 M stock in H~2~O and adjusted to pH 7 with NaOH, and salicylamine and pentyl-pyridoxamine were prepared as 50 mM stocks in H~2~O. All solutions were diluted with H~2~O in order to prepare 20x stock solutions and used as above.

In vitro reactions of OPA with ethanolamine {#s4-12}
-------------------------------------------

OPA was adjusted to 100 μM in 100 μL PBS and to a final concentration of 2% DMSO. Then 10 μL of either neat ethanolamine (or ethanol as control) was added. After 2 hr at 37°C, OPA was extracted using 400 μL of CHCl~3~/MeOH 2:1 (v/v). The lower phase was dried using a stream of nitrogen and resuspended in 100 μL ethanol. The recovery of OPA was assumed to be 100% and the reactions were tested in cell viability assays.

For LC-MS/MS analysis, OPA was adjusted to 0.5 mM in 50 μL H~2~O (4% DMSO) and 3 μL of neat ethanolamine was added to the solution. For the \'ethanolamine only\' control, OPA was replaced by DMSO. For the \'OPA only\' control, no ethanolamine was added. After 2 hr at 37°C, the reactions were diluted 50-fold in MeOH before LC-MS/MS analysis.

LC-MS/MS analysis {#s4-13}
-----------------

LC-MS/MS analysis was performed on a Thermo q-Exactive Plus mass spectrometer coupled to a Thermo Ultimate 3000 uHPLC (Thermo Fisher Scientific). The HPLC method used a Phenomenex (Torrance, CA) Kinetex C18 column (2.6 µm particle size, 10 nm pore size, 150 mm length, and 2.1 mm internal diameter) at a constant flow rate of 0.2 mL/min. Mobile phase A was 0.1% formic acid in H~2~O (v/v) and mobile phase B was 0.1% formic acid in CH~3~CN (v/v). A 10 μL sample was injected onto the column at 0% B and washed at this solvent composition for 3 min. The gradient was first increased to 10% B in 0.1 min and then to 100% B over the next 26.9 min. Detection on the q-Exactive Plus mass spectrometer was performed in positive mode between 300 and 2000 m/z, using an acquisition target of 3E6, and a maximum ion injection time of 200 ms at a resolution of 70,000 for MS and 35,000 for MS/MS data. For MS/MS experiments, \[M + H\]^+^ ions were targeted for isolation and fragmentation at a normalized collision energy of 35 eV.

Ehrlich\'s test {#s4-14}
---------------

A 10 μL sample of OPA 5 mM in DMSO and 5 μL of ethanolamine 1 M (pH 7, prepared above) were added to 85 μL PBS. Control reactions were prepared by either replacing OPA by DMSO or ethanolamine by triethanolamine. After 3 hr at 37°C, OPA was extracted with CHCl~3~/MeOH 2:1 (v/v). The lower phase was dried and resuspended in 35 μL ethanol. Ehrlich\'s reagent was prepared according to [@bib3] (80 mM 4-(dimethylamino)benzaldehyde in MeOH/0.6 M HCl 1:1 (v/v)). The resuspended reactions were diluted to 0.5 mL with H~2~O and then to 1 mL with Ehrlich\'s reagent. After 2 min at 68°C, the solutions were cooled, transferred to a quartz cuvette, and the absorbance was measured between 450 and 700 nm (SpectraMax Plus 384, Molecular Devices, Sunnyvale, CA).

Detection of PE-OPA adducts in vitro {#s4-15}
------------------------------------

A 5.2 μL sample of OPA 5 mM in DMSO and 2 μL of transphosphatidylated chicken egg PE (13 mM in CHCl~3~) were added to 44.8 μL reaction buffer (1 M triethylammonium acetate/CHCl~3~/MeOH 1:1:3 (v/v/v), as described by [@bib55]). Control reactions were performed by replacing either OPA by DMSO, PE by CHCl~3~, or PE by chicken egg PC (13 mM in CHCl~3~). After 3 hr at 37°C, the reactions were diluted to 500 μL with MeOH and 50 μL of the diluted reactions was dried using a stream of nitrogen. After resuspension in 25 μL MeOH, 225 μL PBS was added and the suspension was sonicated in a water bath for 2 min. Then 5 μL (275 U) phospholipase D (PLD) from *Streptomyces chromofuscus* (Enzo Life Sciences) was added and after 16 hr at 37°C, the reaction was extracted with 1 mL CHCl~3~/MeOH 2:1 (v/v). The lower phase was dried, resuspended in 1 mL CHCl~3~, and analyzed by LC-MS/MS.

Detection of PE-OPA adducts in human cells {#s4-16}
------------------------------------------

Cells were seeded at 10% confluence in 100 mm dishes and were grown to 60% confluence in standard conditions. OPA was added to 250 nM for HEK293T and 450 nM for HCT116 in 15 mL complete growth medium. After 24 hr at 37°C and 5% CO~2~, the cells were washed with 15 mL TBS and then resuspended in 20 vol of CHCl~3~/MeOH 2:1 (v/v) and 0.6 vol of pentyl-pyridoxamine 50 mM. After homogenization for 20 min at room temperature, the suspension was extracted using 4 vol of NaCl 0.9%. The lower phase was dried using a stream of nitrogen and resuspended in 100 μL MeOH by sonication. A 50 μL sample of the suspension was diluted to 500 μL in PBS and further sonicated. Then 15 μL PLD (825 U) was added and the suspension was incubated at 37°C for 14 hr. The reaction was extracted with 2 mL CHCl~3~/MeOH 2:1 (v/v) and the lower phase was dried and resuspended in 0.5 mL CHCl~3~/MeOH 2:1 (v/v). A second extraction was performed by addition of 125 μL NaCl 0.9%. The lower phase was dried, resuspended in 180 μL CHCl~3~, and analyzed by LC-MS/MS.

Preparation of large unilamellar vesicles (LUVs) {#s4-17}
------------------------------------------------

Solutions containing a total of 1 mg of dioleoyl-PE and dioleoyl-PC (Avanti Lipids) were prepared from 10 mg/mL stock solutions in CHCl~3~. The solvent was removed from these solutions using first a stream of nitrogen and then by evaporation under vacuum. Lipid films were rehydrated at 37°C for 5 hr with 0.4 mL 100 mM calcein pH 7.4, and homogenized by vortexing and five freeze-thaw cycles. Liposome suspensions were next extruded 20 times through 100 nm polycarbonate filters (Avanti Mini-Extruder) to generate LUVs encapsulating calcein. LUVs were separated from free calcein by gel filtration over Sephadex G-50 using 20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA as buffer. Leakage experiments were started immediately after chromatography.

Liposome leakage assay {#s4-18}
----------------------

A 50 μL sample of calcein-containing LUVs diluted in 20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA was dispensed in 96-well plates. Then 50 μL OPA solution (diluted from 200 stocks in the same buffer as the LUVs) was added to start the leakage assay. The fluorescence of calcein was monitored each 30 s on a Spectramax i3 (Molecular Devices) using excitation at 493 nm and emission at 518 nm over 65 min and at room temperature. Background fluorescence was subtracted for each OPA concentration by using control wells in which calcein-containing LUVs were replaced by buffer. A control using DMSO vehicle instead of OPA was used as the 0% leakage reference and a solution of 0.2% Triton X-100 was used instead of the OPA solution in the 100% leakage reference. For each time point, the fluorescence data were normalized to these two reference samples.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"The anticancer natural product ophiobolin A induces cytotoxicity by covalent modification of phosphatidylethanolamine\" for consideration by *eLife*. Your article has been favorably evaluated by Michael Marletta (Senior editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

This study investigates the basis of ophiobolin A (OPA) cytotoxicity using a genetic screening strategy and followed up with a multi-faceted analysis to reach the surprising conclusion that OPA kills cancer cells by covalently modifying phosphatidylethanolamine (PE). The haploid insertion strategy outlined here is a powerful way to screen for small molecule targets by looking for gene inactivating mutants conferring resistance and it was nicely validated with topoisomerase inhibitors. It was also impressive that the three inactivated genes uncovered in promoting OPA resistance were all part of the PE biosynthetic pathway. Based on the literature and the tendency of OPA to undergo pyrrole formation with primary amines, the authors astutely postulated that PE could be interacting directly with OPA, and this was in fact observed. The authors also found that knockdown of the PE biosynthetic enzymes recapitulated the genetic screen findings about OPA resistance and that PE added exogenously could confer OPA resistance, presumably by titrating OPA out. Overall, this is a fascinating study with a very unusual proposed mechanism of action of a cytotoxic drug. However, it is believed that more compelling evidence is needed to support the conclusion that the PE reaction with OPA is the primary mechanism of action for OPA\'s cell killing.

Requested revisions:

It is somewhat surprising that these modest changes in the levels of PE (16-24%) in the genetic experiments could be so important for the influencing potency of the compound in light of the model for OPA action. In addition, the dose response curve in [Figure 1---figure supplement 4a](#fig1s4){ref-type="fig"}, shows only a very modest effect on OPA IC~50~, and this also leads to questions about the mechanism of action of OPA. It raises the concern that there still is one or more Lys containing protein targets that are of great importance for OPA pharmacology as the authors state has been suggested before. Loss of function screens may have difficulty in revealing the major target of antiproliferative small molecules such as OPA, because inactivation of the very target is expected to recapitulate the cellular phenotype of OPA and the mutant cells would not be viable.

A significant concern relates to a paper that they cite by Dasari et al. (2015) that notes that the 6-epi isomer of OPA is 40-fold less potent than the natural OPA across a panel of cell lines. Since the pyrrole OPA adduct would be the same regardless of the starting stereoisomer of OPA (as this 6-stereocenter is lost as it becomes sp2), one would then have to argue that the rate of pyrrole formation between PE and the 6-epimer is 40-fold slower than the reaction with the natural compound. While not impossible, this large difference in reactivity seems unlikely as there would not appear to be complex recognition involved in the two small molecules coming together. Nevertheless, the PE reactivity mechanistic model should be readily tested by getting some of the 6-epimer from Dasari et al., or some other supplier. If the chemical reactivity of the 6-epimer with PE is indeed slowed by ca. 40-fold as the above analysis predicts, this would be very reassuring for the authors\' model. This model could also be tested by comparing a series of other analogs from Dasari et al. (or other suppliers) and determining the correlation between cell potency and PE reactivity.

If the PE-OPA adduct is indeed responsible for the cytotoxicy of OPA, one might have expected that the addition of exogenous PE could enhance, rather than reduce, the cytotoxicity of OPA. Perhaps the PE-OPA adduct needs to be embedded in the membrane to be toxic. It would be helpful if the authors could perform preparative quantities of the PE-OPA adduct and then add this adduct exogenously to the cell culture medium to explore its potential to be toxic to cell growth.

It is possible that the PE-OPA adduct has unique fluorescence compared with the PE and OPA as isolated molecules. If so, the authors could check to see if OPA addition induces the corresponding fluorescence change that might be detected by cellular imaging. Alternatively, perhaps the authors could check to see if OPA drives leakiness in the cell membrane by allowing normally cell impenetrant colorimetric dyes to accumulate in cells rapidly after OPA administration.

10.7554/eLife.14601.022

Author response

Requested revisions:

It is somewhat surprising that these modest changes in the levels of PE (16-24%) in the genetic experiments could be so important for the influencing potency of the compound in light of the model for OPA action. In addition, the dose response curve in [Figure 1---figure supplement 4a](#fig1s4){ref-type="fig"}, shows only a very modest effect on OPA IC~50~, and this also leads to questions about the mechanism of action of OPA. It raises the concern that there still is one or more Lys containing protein targets that are of great importance for OPA pharmacology as the authors state has been suggested before. Loss of function screens may have difficulty in revealing the major target of antiproliferative small molecules such as OPA, because inactivation of the very target is expected to recapitulate the cellular phenotype of OPA and the mutant cells would not be viable.

While we agree that loss-of-function screens typically cannot be used to directly identify genes that encode targets essential for cell viability, we believe that the results of the haploid genetic screen we performed provide strong evidence that PE is the main target of OPA. We found that genetic inactivation of the Kennedy pathway in KBM7 cells leads to a reduction in total cellular PE levels and a concomitant increase in OPA resistance. We also found that OPA reacts covalently with PE in human cells, leading us to hypothesize that the observed cytotoxicity of OPA reflects the amount of covalent PE-OPA adducts formed in cells.

Although the Kennedy pathway is genetically inactivated in the mutant cells detected as OPA-resistant in our screen, these cells are not devoid of PE, as PE can be synthesized via multiple pathways and cells employ mechanisms to maintain phospholipid homeostasis. As such, these mutant cells have only a 16-24% reduction in PE levels ([Figure 1e](#fig1){ref-type="fig"}), and any phenotype associated with this reduction is therefore likely to be mild. The modest reduction in PE levels was accompanied by a modest increase in the IC~50~ of OPA from 43 nM in wild-type KBM7 cells to 70-85 nM in the mutants ([Figure 1---figure supplement 4a](#fig1s4){ref-type="fig"}). Based on the mechanism of the Paal-Knorr reaction, we surmise that the rate of covalent adduct formation is proportional to both the concentration of OPA and that of PE in the lipid bilayer. Accordingly, a modest reduction in PE levels (less than 2-fold reduction) translates into a modest decrease in the rate of deleterious adduct formation and thus a modest increase in OPA resistance (up to 2-fold). This slight increase in resistance manifests as a quantitatively detectable increase in proliferation rate of the mutants' cells upon OPA treatment in a sensitive, sequencing-based genetic screen output. We used these subtle changes found in the mutant cells to form a hypothesis about the identity of the direct molecular target of OPA in human cells.

The reviewers raise the concern that \"there still is one or more Lys containing protein targets that are of great importance for OPA pharmacology as the authors state has been suggested before\". If lysine-containing protein targets were the major determinants of OPA cytotoxicity rather than PE-OPA adduct formation, a mild decrease in PE content would likely have little or no effect on the resistance to OPA. The results obtained in the haploid genetic screen and the follow-up experiments are fully and quantitatively accounted for by our model of OPA cytotoxicity. We therefore believe that PE-OPA adduct formation is the main determinant of OPA cytotoxicity. We have edited the manuscript to clarify our interpretation of the genetic experiments.

A significant concern relates to a paper that they cite by Dasari et al. (2015) that notes that the 6-epi isomer of OPA is 40-fold less potent than the natural OPA across a panel of cell lines. Since the pyrrole OPA adduct would be the same regardless of the starting stereoisomer of OPA (as this 6-stereocenter is lost as it becomes sp2), one would then have to argue that the rate of pyrrole formation between PE and the 6-epimer is 40-fold slower than the reaction with the natural compound. While not impossible, this large difference in reactivity seems unlikely as there would not appear to be complex recognition involved in the two small molecules coming together. Nevertheless, the PE reactivity mechanistic model should be readily tested by getting some of the 6-epimer from Dasari et al., or some other supplier. If the chemical reactivity of the 6-epimer with PE is indeed slowed by ca. 40-fold as the above analysis predicts, this would be very reassuring for the authors\' model. This model could also be tested by comparing a series of other analogs from Dasari et al. (or other suppliers) and determining the correlation between cell potency and PE reactivity.

As pointed out by the reviewers, Dasari et al. observe a significant difference in potency between 6-*epi*-OPA and OPA across a panel of human cell lines despite the fact that both compounds would form the same pyrrole adduct upon reaction with PE (Dasari et al., 2015). Given our model that cytotoxicity depends on the amounts of PE-OPA adduct formed, this observation must mean that the reaction of PE with 6-*epi-*OPA is on the order of 40-fold slower than the reaction of PE with OPA. The reviewers suggest that this large difference in reactivity is improbable as the initial step in the reaction (hemiaminal formation) is unlikely to be influenced by the stereochemistry of OPA at position 6.

Although we agree with this point, the difference in reactivity between the OPA epimers can readily be explained by considering the rate-limiting step of this reaction. Amarnath et al. observed that the rate limiting step in the Paal-Knorr reaction is the ring cyclization step and not hemiaminal formation (Amarnath et al., 1991). Amarnath et al. also observed that the cyclization step is indeed influenced by the stereochemistry of the 1,4 diketone, and rates of pyrrole formation can be up to 57-fold different between stereoisomers (Amarnath et al., 1991). In light of this careful documentation of the effect of stereochemistry on the rate-limiting step in the Paal-Knorr reaction, the 40-fold difference in potency between OPA and 6-*epi*-OPA can be attributed to a reduction in PE-OPA pyrrole adduct formation.

Lastly, 6-*epi*-OPA cannot be obtained from a commercial supplier, and thus we hope that this theoretical explanation will suffice to satisfy the reviewers regarding this interesting aspect of the Paal-Knorr reaction.

If the PE-OPA adduct is indeed responsible for the cytotoxicy of OPA, one might have expected that the addition of exogenous PE could enhance, rather than reduce, the cytotoxicity of OPA. Perhaps the PE-OPA adduct needs to be embedded in the membrane to be toxic. It would be helpful if the authors could perform preparative quantities of the PE-OPA adduct and then add this adduct exogenously to the cell culture medium to explore its potential to be toxic to cell growth.

The reviewers state that \"one might have expected that the addition of exogenous PE could enhance, rather than reduce, the cytotoxicity of OPA\". According to our model, the addition of exogenous PE could indeed lead to an increase in cytotoxicity if it results in an increase in the amount of cytotoxic PE-OPA adducts in the cell membrane. However, this result would only be obtained in hypothetical scenarios such as: (1) exogenous PE can efficiently partition to the cell membrane when added to aqueous culture medium and the increase in lipid bilayer PE content leads to an increase in PE-OPA adduct formation; or (2) covalent PE-OPA adducts formed in the cell culture medium can partition efficiently into the lipid bilayer in a manner which retains their cytotoxic potential.

Our experiments clearly show that addition of exogenous PE to the growth medium of HEK293T cells reduces the cytotoxicity of OPA ([Figure 3a](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). To explain this data, we surmise that OPA reacts with the exogenously added PE in the growth medium and that the large majority of these adducts do not partition into the cell membrane, thereby reducing the number of OPA molecules available to partition into the cell membrane, react with endogenous PE, and induce cell death. Supporting this assertion is the fact that the solubility of PE in aqueous solutions is very low, and thus exogenous PE forms visible insoluble aggregates when added to cell culture medium. Thus, any OPA reacting with exogenously added PE will likely remain trapped in these aggregates as the PE-OPA adducts are themselves also very hydrophobic.

We edited the manuscript to clarify our prediction of the effect of exogenous PE addition to cells treated with OPA.

The reviewers suggest that we generate \"preparative quantities of the PE-OPA adduct and then add this adduct exogenously to the cell culture medium to explore its potential to be toxic to cell growth\". This experiment is conceptually an outstanding way of proving the role of PE-OPA adducts in the observed cytotoxicity of OPA and would provide a strong validation of our mechanism of action. However, this experiment is technically challenging as hydrophobic PE-OPA adducts need to be delivered to cells in sufficient amounts, and their final membrane orientation must mimic that of endogenously generated adducts.

We attempted the suggested adduct delivery experiment using two approaches. We first synthesized preparative amounts of PE-OPA adduct and dissolved the synthesized molecule in DMSO. We then added the synthesized adduct to HEK293T cells at final concentrations of up to 100 μM but did not observe any cytotoxicity. As mentioned earlier, we believe that this is because the PE-OPA adduct is extremely hydrophobic and its solubility in aqueous solutions is accordingly low. We believe that upon addition to cell culture medium, the adduct forms insoluble aggregates and cannot partition into the cell membrane to a sufficient degree to cause toxicity.

In order to circumvent the problem of inefficient delivery of hydrophobic molecules to animal cells, we next attempted liposomal delivery of the adduct. We incorporated pre-formed PE-OPA adduct into fusogenic liposomes using Ibidi\'s Fuse-it-L commercial reagent and added the prepared liposomes to HEK293T cells, but were also not able to observe significant cytotoxicity. We believe this can be explained by the difficulty in delivering sufficient quantities of adduct using this system which is typically used to deliver analytical quantities of fluorescent probes. This difficulty is likely exacerbated by the strong lipid bilayer destabilization effect of the adduct as observed in the liposome leakage assay described above -- any liposomes with significant quantities of PE-OPA adduct would likely be structurally unstable, perhaps impairing or reducing fusion with the cell membrane.

It is possible that the PE-OPA adduct has unique fluorescence compared with the PE and OPA as isolated molecules. If so, the authors could check to see if OPA addition induces the corresponding fluorescence change that might be detected by cellular imaging. Alternatively, perhaps the authors could check to see if OPA drives leakiness in the cell membrane by allowing normally cell impenetrant colorimetric dyes to accumulate in cells rapidly after OPA administration.

Unlike PE and OPA, the PE-OPA adduct contains a pyrrole moiety that weakly absorbs in the near ultraviolet range of the electromagnetic spectrum. However, this weak absorption lies in a spectral region that is subject to significant cellular auto-fluorescence, and therefore is not suitable for fluorescence imaging. Additionally, it is unlikely that the fluorescence of the PE-OPA adduct will be distinguishable from that of OPA adducts formed by reaction with other primary amines, and therefore this experiment would not provide further evidence supporting PE as the primary molecular target of OPA.

According to our model of the mechanism of action of OPA, the formation of PE-OPA adducts leads to adverse structural effects on the lipid bilayer and ultimately to cell death. As suggested by the reviewers, we should therefore be able to detect cell membrane leakiness induced by OPA treatment. However, these experiments must be able to distinguish between cell membrane leakiness induced directly by PE-OPA adduct formation and leakiness due to downstream effects of cell death and lysis through an unrelated mechanism of action. In addition, it was important for us to prove that leakiness depends not only on OPA concentration but also on PE levels in the lipid bilayer, as this must be true if the increase in resistance to OPA we observed in Kennedy pathway mutants is due to reduced PE levels.

To address these points, we tested if OPA induces membrane leakiness in vitro using artificial liposomes. We prepared liposomes loaded with the fluorescent dye calcein using a variable ratio of dioleoyl-PE to dioleoyl-PC. As calcein fluorescence becomes dequenched upon release from liposomes and resulting dilution, an increase in the fluorescence of the aqueous solution containing liposomes can be used as an indicator of liposome leakage. Excitingly, we observed that OPA treatment caused extensive liposome leakage, and that the leakage was directly proportional to the PE content of the liposomes ([Figure 5a](#fig5){ref-type="fig"}). Importantly, we observed that liposomes composed only of PC or with very low PE content remain intact even at high OPA concentration, indicating that the leakage is likely specifically due to the presence of PE-OPA adducts. These results clearly show that OPA destabilizes lipid bilayers and thereby support our conclusion that formation of PE-OPA adducts is a primary mechanism of cytotoxicity.
